ndothelial progenitor cells (EPCs) are a subset of pluripotent ''stem cells'' derived from the bone marrow that can circulate in the blood. Release of EPCs from the marrow occurs in response to chemokines produced as a result of remote injury. The scientific evidence to date suggests that EPCs then home to injury sites, thereby contributing to tissue revascularisation and regeneration. 1 EPC populations can be isolated and cultured from a number of sources such as CD14-positive, CD34-positive, and CD133-positive haematopoietic cells from peripheral or fetal cord blood and human bone marrow. Additional reservoirs of EPCs, including the vessel wall itself, may yet be defined. Although the exact molecular characterisation of EPCs is still uncertain, they have been shown to express the endothelial markers von Willebrand factor (vWF), vascular endothelial growth factor-2 receptor (VEGF2R), VEcadherin, PECAM-1 (CD31), Tie 1, Tie 2, and E-selectin among others. 1 Studies to date have been hampered by the lack of more discriminatory endothelial markers and functional assays to distinguish EPCs from circulating mature vessel wall endothelial cells or haematopoietic cells. The best marker so far appears to be a haematopoietic stem cell marker called AC133 (CD133), a 5-transmembrane glycoprotein of unclear function which is lost in mature adherent endothelial cells. Accordingly, populations of CD34+ EPCs have the molecular signature AC133+ VEGFR2+ and represent functional endothelial precursors. 2 The numbers of EPCs in the circulation can be increased by a variety of means-for example, vascular trauma, 3 physical training, 4 cytokines, 5 drugs 6 and other as yet unknown stimuli. Indeed, one might predict that production and lifespan of EPCs might also be wholly or in part dependent on the individual genotype of genes influencing endothelial cell lifespan.
Mobilisation of precursors from the bone marrow depends on the activation of metalloproteinases that act to release EPCs from the stroma and upregulation of adhesion molecules that facilitate trafficking of the EPCs into the circulation via the sinusoids. VEGF and G-CSF are known to be principal factors in this regard. 7 
TRANSDIFFERENTIATION
The
8 Bone marrow precursors differentiated into VSMC have also been identified in histological samples of human atheroma from sex mismatched bone marrow transplant patients with coronary artery disease. 9 Once the genetic and cellular mechanisms that influence transdifferentiation are clear, the biological potential of EPCs could be exploited further for repair purposes.
Why should we be excited about EPCs? Quite simply, because they have radically altered the way in which vascular biologists and clinicians think about the genesis, development, and healing of atherosclerotic lesions. As a result, in addition to understanding the local environment of the arterial wall, we should now consider the ability of EPCs to modulate lesion development. Although there is evidence that EPCs integrate into injury sites in mouse models, 8 seed implanted coronary devices, 10 and damage large or adventitial vessels after cardiac transplantation in humans, 11 the mechanisms by which they recognise damaged and dysfunctional endothelium, whether they divide, migrate or transdifferentiate before or after they enter the vessel wall, remain unclear.
CARDIOVASCULAR RISK
Furthermore, recent literature has demonstrated a clear link between circulating numbers of EPCs and cardiovascular risk. Despite the relatively crude and various methods of isolation, characterisation, and subsequent culture of EPCs, the reports to date show a decrease in EPCs with cumulative cardiovascular risk. 12 In this issue of Heart, Eizawa and colleagues 13 show that diabetes is a significant independent predictor of decreased numbers of CD34-positive cells in the peripheral blood of patients with stable coronary artery disease compared with age matched controls.
There are still questions. Among the most pressing are for the clear use of the acronyms that define EPCs in all their various guises, along with identification of unambiguous unique surface markers and genome expression that define the cell's position within the endothelial cell maturation pathway. Laboratory conditions for the ideal growth and expansion of EPCs, knowledge of the homing signals to normal and diseased vessel walls, genetic propensity for decreased production of EPCs, transduction of EPC with key regulators of differentiation, and ligand targeting of EPCs for delivery to injured sites within the vasculature are all key stimulating research areas.
Should we be at all cautious about the future use of EPCs? Perhaps, but then, not since the Russell Ross ''response to injury hypothesis'' for the development of the atherosclerotic lesion 14 15 has vascular biology experienced such a paradigm shift in its thinking on arterial wall repair.
I strongly believe that we should seize this opportunity to modify our current thinking on the pathobiology of arterial disease towards the restoration of endothelial function by EPC based therapies. 
